Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:45 pm Purchase | 2024-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Longitude Capital Partners IV LLC | 2,765,381 8.400% | 198,281 (+7.72%) | Filing History |
| 2024-11-04 7:49 pm Purchase | 2024-10-31 | 13D | Vera Therapeutics, Inc. VERA | Longitude Capital Partners IV LLC | 5,184,062 8.400% | 20,000 (+0.39%) | Filing History |
| 2024-10-22 4:20 pm Purchase | 2024-10-15 | 13D | CeriBell, Inc. CBLL | Longitude Capital Partners IV LLC | 2,475,110 7.000% | 2,475,110 (New Position) | Filing History |
| 2024-09-23 8:11 pm Purchase | 2024-09-16 | 13D | Bicara Therapeutics Inc. Common Stock BCAX | Longitude Capital Partners IV LLC | 2,501,934 6.000% | 2,501,934 (New Position) | Filing History |
| 2024-02-13 4:43 pm Purchase | 2023-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Longitude Capital Partners IV LLC | 2,567,100 9.600% | 2,567,100 (New Position) | Filing History |
| 2024-02-05 4:45 pm Purchase | 2024-02-01 | 13D | Vera Therapeutics, Inc. VERA | Longitude Capital Partners IV LLC | 5,164,062 9.800% | 9,925 (+0.19%) | Filing History |
| 2024-02-05 4:40 pm Purchase | 2024-01-29 | 13G | CG Oncology, Inc. Common stock CGON | Longitude Capital Partners IV LLC | 4,662,281 7.000% | 4,662,281 (New Position) | Filing History |
| 2023-02-16 4:40 pm Purchase | 2023-02-06 | 13D | Vera Therapeutics, Inc. VERA | Longitude Capital Partners IV LLC | 5,154,137 12.300% | 1,714,285 (+49.84%) | Filing History |
| 2022-04-05 07:36 am Purchase | 2022-02-10 | 13D | Vera Therapeutics, Inc. VERA | Longitude Capital Partners IV LLC | 3,439,852 12.700% | 343,258 (+11.09%) | Filing History |
| 2021-05-27 4:45 pm Sale | 2021-05-17 | 13D | Eargo, Inc. EAR | Longitude Capital Partners IV LLC | 58,474,060 4.900% | -88,880 (-0.15%) | Filing History |
| 2021-05-27 4:32 pm Purchase | 2021-05-18 | 13D | Vera Therapeutics, Inc. VERA | Longitude Capital Partners IV LLC | 3,096,594 15.100% | 3,096,594 (New Position) | Filing History |
| 2021-04-26 4:55 pm Sale | 2021-04-14 | 13D | Eargo, Inc. EAR | Longitude Capital Partners IV LLC | 58,562,940 7.600% | -19,833,100 (-25.30%) | Filing History |
| 2020-10-30 4:24 pm Purchase | 2020-10-22 | 13D | Eargo, Inc. EAR | Longitude Capital Partners IV LLC | 78,396,040 10.500% | 78,396,040 (New Position) | Filing History |